Protalix BioTherapeutics (PLX) Free Cash Flow (2010 - 2026)

Protalix BioTherapeutics' Free Cash Flow history runs 17 years deep, the most recent figure standing at $21.7 million for Q1 2026.

• In Q1 2026, Free Cash Flow rose 496.34% year-over-year to $21.7 million; the TTM figure through Mar 2026 stood at $14.9 million (up 2369.01% YoY), while the FY2025 annual figure was -$12.4 million, down 246.82% from the prior year.
• Free Cash Flow was $21.7 million for Q1 2026 at Protalix BioTherapeutics, up from $2.9 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $21.7 million in Q1 2026 to a low of -$9.3 million in Q3 2022.
• Historically, Free Cash Flow has averaged -$545764.7 across 5 years, with a median of -$3.1 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Free Cash Flow slumped 319.42% in 2022, then jumped 496.34% in 2026.
• A 5-year view of Free Cash Flow shows it stood at -$2.5 million in 2022, then jumped by 226.87% to $3.2 million in 2023, then surged by 42.05% to $4.6 million in 2024, then sank by 36.96% to $2.9 million in 2025, then soared by 650.66% to $21.7 million in 2026.
• The last three Free Cash Flow figures came in at $21.7 million (Q1 2026), $2.9 million (Q4 2025), and -$4.2 million (Q3 2025), per Business Quant data.